Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?
The management of chronic hepatitis B virus (CHB) infection is an area of massive unmet clinical need worldwide. In spite of the development of powerful nucleoside/nucleotide analogue (NUC) drugs, and the widespread use of immune stimulators such as interferon-alpha (IFNα) or PEGylated interferon-al...
Main Authors: | Ganesh Selvaraj Duraisamy, Dattatry Bhosale, Ivana Lipenská, Ivana Huvarova, Daniel Růžek, Marc Windisch, Andrew D. Miller |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/12/9/998 |
Similar Items
-
Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
by: Lívia do Carmo Silva, et al.
Published: (2020-11-01) -
Where we are, where we are going
by: Teresa Bermejo-Vicedo, et al.
Published: (2020-03-01) -
Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go
by: Ruggero De Maria Marchiano, et al.
Published: (2021-03-01) -
Precision medicine in COPD: where are we and where do we need to go?
by: Venkataramana K. Sidhaye, et al.
Published: (2018-08-01) -
Gravitational waves: where we are, where we go
by: Ricci Fulvio
Published: (2019-01-01)